Padmanabhan PK, Ferreira GR, Zghidi-Abouzid O, Oliveira C, Dumas C, Mariz FC, et al
ADA 2024) showed combination benefit in obese rats
21 Several incretin-based therapies, including liraglutide, dulaglutide, semaglutide, and tirzepatide, are currently approved for patients with type 2 diabetes ( Table )
A licensed healthcare provider must evaluate your medical history, current health status, and specific needs to determine if GLP-1 (T) Daily ODT dissolvable tablet is appropriate for you
Comparisons with Naltrexone/Bupropion (HR 0.55, 95% CI 0.161.95, p = 0.35) and Phentermine (HR 1.87, 95% CI 0.3410.23, p = 0.46) showed no significant differences
From sourcing top-quality ingredients to working with the best manufacturers in the business, their science-based approach to nutrition sets them apart